Human innate lymphoid cell precursors: identification, characterization, applications
Abstract
Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES + NK cells, T-BET + ILC1, GATA-3 + ILC2 and for IL-22 + but not for IL-17A + ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.
Claims
exact text as granted — not AI-modified1 - 15 . (canceled)
16 . A purified population of innate lymphoid cell precursors (ILCPs), wherein at least 75% of the cells in the population have the phenotype
CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+, CD127+CD1 17+CD3-CRTh2-CD7+CD94-NKp44-CD62L+, or CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+CD62L+.
17 . The purified population of ILCPs of claim 16 , wherein at least 90% of the cells in the population have the phenotype
CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+, CD127+CD1 17+CD3-CRTh2-CD7+CD94-NKp44-CD62L+, or CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+CD62L+.
18 . The purified population of ILCPs of claim 16 , wherein at least 75% of the cells in the population have the phenotype CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+.
19 . The purified population of ILCPs of claim 16 , wherein at least 75% of the cells in the population have the phenotype CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD62L+.
20 . The purified population of ILCPs of claim 16 , wherein at least 75% of the cells in the population have the phenotype CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+CD62L+.
21 . The purified population of ILCPs of claim 17 , wherein at least 90% of the cells in the population have the phenotype CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+.
22 . The purified population of ILCPs of claim 17 , wherein at least 90% of the cells in the population have the phenotype CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD62L+.
23 . The purified population of ILCPs of claim 17 , wherein at least 90% of the cells in the population have the phenotype CD127+CD117+CD3-CRTh2-CD7+CD94-NKp44-CD26+CD62L+.
24 . The purified population of ILCPs of claim 21 , comprising at least 10 4 ILCPs cells.
25 . The purified population of ILCPs of claim 22 , comprising at least 10 4 ILCPs cells.
26 . The purified population of ILCPs of claim 23 , comprising at least 10 4 ILCPs cells.
27 . The purified population of ILCPs of claim 21 , comprising at least 10 6 ILCPs cells.
28 . The purified population of ILCPs of claim 22 , comprising at least 10 6 ILCPs cells.
29 . The purified population of ILCPs of claim 23 , comprising at least 10 6 ILCPs cells.
30 . The purified population of ILCPs of claim 24 , in a medium containing IL-2 and IL-1β.
31 . The purified population of ILCPs of claim 25 , in a medium containing IL-2 and IL-1β.
32 . The purified population of ILCPs of claim 26 , in a medium containing L-2 and IL-1β.
33 . The purified population of ILCPs of claim 27 , in a medium containing IL-2 and IL-1β.
34 . The purified population of ILCPs of claim 28 , in a medium containing IL-2 and IL-1β.
35 . The purified population of ILCPs of claim 29 , in a medium containing IL-2 and IL-1β.Join the waitlist — get patent alerts
Track US2023323304A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.